Actively Recruiting
Evaluation of HuL001 Combined With Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients
Led by HuniLife Biotechnology, Inc. · Updated on 2026-09-18
21
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of the antibody drug HuL001 with Lenalidomide and Dexamethasone to treat adults with relapsed or refractory Multiple Myeloma. This study aims to assess both the safety and tolerability as well as the effectiveness of this therapeutic combination in patients who have had prior treatments. The trial includes a dose escalation phase followed by a dose expansion phase to determine appropriate dosing levels. Participants will receive HuL001 antibody injections every two weeks. They will also take Lenalidomide daily for 21 consecutive days each month and Dexamethasone once every week. The study includes a dose escalation phase with increasing doses of HuL001 and a dose expansion phase at the recommended dose. Throughout the treatment period, participants will visit the clinic on scheduled days for checkups and tests. During the study, participants will be closely monitored through clinical assessments, symptom diaries, and evaluations of their Myeloma response using established criteria. Researchers will track disease responses such as complete and partial remission and observe safety parameters including treatment-related adverse events. The treatment period and outcome assessments last up to eight months, with ongoing monitoring to evaluate immunogenicity and other safety factors.
CONDITIONS
Brief Title
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
Research Team
Z
Zoe Chan, master
M
Maisie Huang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here